Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates

被引：28

作者：

Girard, Nicolas ^{[1
]}

机构：

[1] Inst Curie, Inst Thorax Curie Montsouris, Thorac Surg, Paris, France

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 25期

关键词：

non-small-cell lung cancer; T790M; treatment sequencing; TYROSINE KINASE INHIBITOR; QUALITY-OF-LIFE; OPEN-LABEL; 1ST-LINE TREATMENT; PHASE-III; REAL-WORLD; MEDIATED RESISTANCE; AFATINIB TREATMENT; SURVIVAL-DATA; CHEMOTHERAPY;

D O I：

10.2217/fon-2019-0400

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The availability of several EGFR tyrosine kinase inhibitors (TKIs) for the treatment of EGFR mutation-positive NSCLC poses important questions regarding the optimum sequence of therapy. A key consideration is how best to use the third-generation TKI, osimertinib. While osimertinib has demonstrated impressive efficacy and tolerability in a first-line setting, there are currently no standard targeted treatment options following progression. There is an argument, therefore, for reserving osimertinib for second-line use in patients who acquire the T790M resistance mutation after first- or second-generation TKIs. This article reviews recent clinical studies that have assessed the activity of sequential EGFR TKI regimens. These studies support the hypothesis that sequential use of EGFR TKIs represents a viable treatment option in 'real-world' clinical practice.

引用

页码：2983 / 2997

页数：15

共 78 条

[51]

Roeper J, 2017, ANN ONCOL, V28

[52] Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial [J].

Rosell, Rafael ;

Dafni, Urania ;

Felip, Enriqueta ;

Curioni-Fontecedro, Alessandra ;

Gautschi, Oliver ;

Peters, Solange ;

Massuti, Bartomeu ;

Palmero, Ramon ;

Ponce Aix, Santiago ;

Carcereny, Enric ;

Frueh, Martin ;

Pless, Miklos ;

Popat, Sanjay ;

Kotsakis, Athanasios ;

Cuffe, Sinead ;

Bidoli, Paolo ;

Favaretto, Adolfo ;

Froesch, Patrizia ;

Reguart, Noemi ;

Puente, Javier ;

Coate, Linda ;

Barlesi, Fabrice ;

Rauch, Daniel ;

Thomas, Michael ;

Camps, Carlos ;

Gomez-Codina, Jose ;

Majem, Margarita ;

Porta, Rut ;

Shah, Riyaz ;

Hanrahan, Emer ;

Kammler, Roswitha ;

Ruepp, Barbara ;

Rabaglio, Manuela ;

Kassapian, Marie ;

Karachaliou, Niki ;

Tam, Rachel ;

Shames, David S. ;

Molina-Vila, Miguel A. ;

Stahel, Rolf A. .

LANCET RESPIRATORY MEDICINE, 2017, 5 (05) :435-444

[53] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[54] Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial [J].

Saito, Haruhiro ;

Fukuhara, Tatsuro ;

Furuya, Naoki ;

Watanabe, Kana ;

Sugawara, Shunichi ;

Iwasawa, Shunichiro ;

Tsunezuka, Yoshio ;

Yamaguchi, Ou ;

Okada, Morihito ;

Yoshimori, Kozo ;

Nakachi, Ichiro ;

Gemma, Akihiko ;

Azuma, Koichi ;

Kurimoto, Futoshi ;

Tsubata, Yukari ;

Fujita, Yuka ;

Nagashima, Hiromi ;

Asai, Gyo ;

Watanabe, Satoshi ;

Miyazaki, Masaki ;

Hagiwara, Koichi ;

Nukiwa, Toshihiro ;

Morita, Satoshi ;

Kobayashi, Kunihiko ;

Maemondo, Makoto .

LANCET ONCOLOGY, 2019, 20 (05) :625-635

[55]

SCHOENFELD AJ, 2019, J CLIN ONCOL S, V37

[56] First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression [J].

Schuler, Martin ;

Tan, Eng-Huat ;

O'Byrne, Kenneth ;

Zhang, Li ;

Boyer, Michael ;

Mok, Tony ;

Hirsh, Vera ;

Yang, James Chih-Hsin ;

Lee, Ki Hyeong ;

Lu, Shun ;

Shi, Yuankai ;

Kim, Sang-We ;

Laskin, Janessa ;

Kim, Dong-Wan ;

Arvis, Catherine Dubos ;

Kolbeck, Karl ;

Massey, Dan ;

Maerten, Angela ;

Paz-Ares, Luis ;

Park, Keunchil .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (06) :1569-1579

[57] First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases [J].

Schuler, Martin ;

Wu, Yi-Long ;

Hirsh, Vera ;

O'Byrne, Kenneth ;

Yamamoto, Nobuyuki ;

Mok, Tony ;

Popat, Sanjay ;

Sequist, Lecia V. ;

Massey, Dan ;

Zazulina, Victoria ;

Yang, James C. -H. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) :380-390

[58] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations [J].

Sequist, Lecia V. ;

Yang, James Chih-Hsin ;

Yamamoto, Nobuyuki ;

O'Byrne, Kenneth ;

Hirsh, Vera ;

Mok, Tony ;

Geater, Sarayut Lucien ;

Orlov, Sergey ;

Tsai, Chun-Ming ;

Boyer, Michael ;

Su, Wu-Chou ;

Bennouna, Jaafar ;

Kato, Terufumi ;

Gorbunova, Vera ;

Lee, Ki Hyeong ;

Shah, Riyaz ;

Massey, Dan ;

Zazulina, Victoria ;

Shahidi, Mehdi ;

Schuler, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3327-+

[59] Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors [J].

Sequist, Lecia V. ;

Waltman, Belinda A. ;

Dias-Santagata, Dora ;

Digumarthy, Subba ;

Turke, Alexa B. ;

Fidias, Panos ;

Bergethon, Kristin ;

Shaw, Alice T. ;

Gettinger, Scott ;

Cosper, Arjola K. ;

Akhavanfard, Sara ;

Heist, Rebecca S. ;

Temel, Jennifer ;

Christensen, James G. ;

Wain, John C. ;

Lynch, Thomas J. ;

Vernovsky, Kathy ;

Mark, Eugene J. ;

Lanuti, Michael ;

Iafrate, A. John ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (75)

[60] Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study [J].

Seto, Takashi ;

Kato, Terufumi ;

Nishio, Makoto ;

Goto, Koichi ;

Atagi, Shinji ;

Hosomi, Yukio ;

Yamamoto, Noboru ;

Hida, Toyoaki ;

Maemondo, Makoto ;

Nakagawa, Kazuhiko ;

Nagase, Seisuke ;

Okamoto, Isamu ;

Yamanaka, Takeharu ;

Tajima, Kosei ;

Harada, Ryosuke ;

Fukuoka, Masahiro ;

Yamamoto, Nobuyuki .

LANCET ONCOLOGY, 2014, 15 (11) :1236-1244

← 1 2 3 4 5 6 7 8 →